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Abstract
The role of placebo and nocebo effects—that is positive or negative treatment effects 
that are entirely a consequence of the patient’s expectations and beliefs about a treat-
ment outcome in terms of efficacy, safety, usability or side effects—has been shown for 
almost all types of diseases and physiological response systems. Evidence for the rele-
vance of placebo and nocebo effects in dermatology is also increasing, particularly for 
symptoms of itch and learned (conditioned) immune function. In addition, increasing 
knowledge is available about the neurobiological mechanisms of action, such as the role 
of the dopaminergic system. Studies on this topic offer innovative perspectives to un-
ravel the multifactorial pathways of treatment effects and to use research designs for 
experimental research that provide full insight into the role of placebo and nocebo ef-
fects. Moreover, intervention strategies can be developed for dermatology practice that 
optimize regular treatments with innovative non- pharmacological treatment strategies 
(e.g. optimized doctor–patient communication and treatment adherence, or prevention 
of nocebo reactions with regard to adverse side effects). In addition, evidence on learned 
immune function offers new pathways to optimize pharmacological treatments (e.g. dos-
age adjustments and conditioning of physiological responses), the ultimate goal being to 
prevent individual treatment failures and maximize regular treatment effects.
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1  | INTRODUCTION
A large proportion of the success or failure of dermatological treat-
ment can be explained by factors other than the treatment mecha-
nisms themselves. Placebo and nocebo effects, in particular, strongly 
contribute to treatment outcomes, with explained variances compara-
ble to, for example, effects of analgesics or antidepressants (s1–s5).1,2 
Placebo and nocebo effects are positive or negative treatment effects 
that are a consequence not of the treatment itself, but exclusively of 
the patient’s expectations and beliefs about a more or less benefi-
cial treatment outcome in terms of efficacy, safety, usability or side 
effects.1,2 The relevance of these placebo and nocebo effects has 
been demonstrated for almost all types of conditions and physiological 
response systems (e.g. immune and endocrine functioning) (s6–s12). 
The increasing evidence for placebo and nocebo effects in the field 
of dermatology has scientific and clinically relevant implications for 
experimental research designs as well as innovative (non- )pharmaco-
logical treatment strategies (s13–s15).
2  | WHAT IS THE EVIDENCE FOR 
PLACEBO AND NOCEBO EFFECTS IN 
DERMATOLOGY?
Indirect evidence for the role of placebo and nocebo effects in der-
matology comes from contagious itch: itch sensations (in contrast to 
other physical sensations or noxious stimuli) are highly suggestible, 
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with both humans and animals starting to scratch themselves after 
viewing others scratching (s16–s18). Direct evidence for placebo and 
nocebo induction on itch has been delivered by experimental studies 
that support the role of both conscious and automatic learning pro-
cesses, such as verbal suggestions and conditioning (s19–s22).3–5 In 
one of the first experiments, negative suggestions about a histamine 
application resulted in higher itch scores (s19). In a study comparing 
itch and pain symptoms, nocebo effects were induced for both itch 
and pain after the verbal suggestion that the majority of subjects gen-
erally experienced high levels of itch or pain in response to the stimuli 
applied.3 In line with research in other areas, such as pain, placebo and 
nocebo effects on itch can be induced most effectively by combin-
ing automatic and conscious processes, specifically conditioning and 
verbal suggestions (s20–s22).4,5 These effects also play a role in der-
matological research and practice, as is shown by a meta- analysis of 
clinical trials of oral systemic medication for psoriasis, atopic dermati-
tis and urticaria, showing moderate to large effects on itch of placebo 
medication (without any treatment ingredients).6 These experimental 
and clinical studies clearly demonstrate the significance of placebo 
and nocebo effects in itch treatments and offers possible explana-
tions for itch sensitization in patients suffering from chronic itch 
(s23). Preliminary evidence for the possible neurobiological pathways 
comes from a study examining nocebo effects in itch in patients with 
atopic dermatitis,4 showing that when applying saline while patients 
expected a real allergen, similar brain responses were observed as 
with the previously applied real allergen, with greater activation in the 
striatum and the dorsolateral prefrontal cortex. These regions have 
previously also been linked to placebo- or nocebo- induced brain pro-
cesses related to pain and its regulation (s24–s25).
Placebo and nocebo effects have also been shown to impact phys-
iological pathways. Animal and human studies have shown that phys-
iological reactions of histamine release, for example, can be the result 
of learning processes such as conditioning (s6–s10).1 In conditioning 
trials, a pharmacological agent such as cyclosporine is combined with 
a neutral cue such as a specific beverage. When later exposed only 
to the beverage, as a conditioned stimulus, participants show com-
parable immune reactions as previously to the drug. Specific endo-
crine reactions, such as insulin reactions, have also been shown to be 
susceptible to conditioning (s10–s11). Particularly relevant for derma-
tology are the animal and human studies of conditioning anti- allergic 
reactions (s7, s9).7,8 In the first study in humans, patients with allergies 
were given an antihistamine in combination with a distinct beverage 
for several days. When the patients were later exposed only to the bev-
erage, they had less severe subjective symptoms and a reduced skin 
response (smaller wheal size and less basophil activation) to the skin 
prick test.7 Results were replicated in part,8 but much more evidence 
in this area is needed. Finally, placebo mechanisms with conditioning 
have also been applied in a clinical dermatological trial, showing com-
parable treatment effects and relapse rates when patients with psori-
asis were treated in a conditioning design with about half of the doses 
of the topical corticosteroid treatments.9
Although results in the area of dermatology are relatively scarce 
and limited to the fields of itch (e.g. atopic eczema), allergic responses 
(e.g. house dust mite) or responses to topical corticosteroid treatments 
(e.g. psoriasis), these results strongly suggest that placebo and nocebo 
effects play a similar role as in other conditions (e.g. pain, Parkinson, 
depression) (s6–s12). Future research on the neurobiological effects 
and mechanisms in other dermatological conditions (e.g. acne, rosa-
cea, lupus) as well as subgroups of patients (e.g. children with eczema) 
is clearly wanted.
3  | HOW PLACEBO AND NOCEBO EFFECTS 
WORK AND AFFECT BODILY FUNCTIONS
Research has evolved our understanding about the specific psycho-
neurobiological mechanisms through which placebo and nocebo 
effects work. Placebo effects influence treatments through mecha-
nisms of expectancies; these include conscious learning processes, 
such as verbal suggestions and instructions by a doctor, and more 
automatic learning processes of conditioning (s2, s15).1,2 The most 
effective strategy for reducing acute symptoms during a medical 
procedure appears to be verbal suggestions, for example by a medi-
cal doctor before surgery (s26). To obtain more stable placebo and 
nocebo effects, the combination of both conscious and automatic 
processes is most effective, as has been shown for a broad variety of 
symptoms and conditions, including itch (s2, s15).1,2 For these longer- 
term placebo or nocebo effects, conditioning is a necessary learning 
mechanism, particularly when focusing on changes in the physiologi-
cal response systems, such as immune and endocrine functioning (s6–
s10). Conditioning as a learning mechanism can also explain the large 
role of individual and environmental influences—such as personality 
characteristics of patients and doctors’ white coats or technical instru-
ments—on the effectiveness of the placebo or nocebo effect for a spe-
cific treatment (s3- s5).1,2 There is, for example, preliminary evidence 
that placebo effects vary with regard to the type of treatment (e.g. 
larger effects for intra- articular, subcutaneous and topical treatments 
than for oral treatments, and stimulant effects for red oral drugs (s27–
s29), age groups (e.g. possibly stronger effects in children) (s30–s31), 
individual differences between patients (e.g. stronger placebo effects 
for more optimistic individuals and stronger nocebo effects for indi-
viduals with more worrying and negative attitudes towards medi-
cation)5 (s5, s24, s32) and cultural differences (e.g. particular large 
placebo analgesic effects in US trials, possibly due to cultural differ-
ences in communication styles about expected drug effects) (s33).
Different neurobiological pathways have been established for these 
learning mechanisms of expectancies, with most research conducted 
in the field of pain (s1, s8).1,2 The first neurobiological pathways were 
revealed by conditioning experiments that induced placebo responses 
of analgesic treatment; these placebo responses could be blocked 
when administering an opioid antagonist (e.g. naloxone).1 Since then, 
several other possible physiological pathways have been shown in 
various symptoms and conditions (s34). For example, proglumide 
(a CCK- Cholecystokinin antagonist) has been shown to facilitate placebo 
analgesics and inhibit nocebo hyperalgesics (s34).1 In addition, specific 
immune and endocrine responses are known to co- occur with placebo 
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and nocebo learning processes, as shown by immune and endocrine 
conditioning studies (e.g. IL- 2, cortisol) (s6–s10). The related neurobi-
ological processes of these learning mechanisms are also increasingly 
being disentangled, indicating for example specific areas of the prefron-
tal cortex and amygdala that are associated with learning processes of 
placebo and nocebo effects (s24–s25). These pathways seem at least 
partly dependent on the specific type of treatment (e.g. opioids for 
analgesic treatment), possibly due to specific conditioning effects of the 
drug (s34). However, possible affect- related pathways have also been 
identified that appear to be related to the reward or fear function of 
placebo and nocebo effects. For example, dysregulated dopaminergic 
and cortisol responses are involved in positive and negative expecta-
tion learning and memory processes of placebo and nocebo effects (s2, 
s35–s36).1,2 Placebo and nocebo effects have finally shown to be also 
influenced by genotypes (e.g. specific COMT genotypes) (s35).1,2
4  | WHAT ARE THE IMPLICATIONS OF 
PLACEBO AND NOCEBO EFFECTS FOR 
DERMATOLOGICAL PRACTICE?
Particularly the neurobiological insights into how placebo and nocebo 
effects affect bodily functions contributed to the renewed research 
attention in this area. This may also have important implications for 
dermatological research and practice.
1. Dermatologists and their patients need to be aware that treat-
ment outcomes in terms of efficacy and side effects can be 
partly attributed to their expectations about the treatments.
Although there are no precise effect sizes of placebo and nocebo 
effects in the area of dermatology yet, results suggest that effects on itch 
are at least similar as or even stronger than on pain.3,6 This is possibly 
due to the high suggestibility of itch. Also, animal and human studies 
have yielded convincing evidence that learned (conditioned) immune 
functioning is possible (e.g. conditioning of antihistamines or cyclospo-
rine) (s6–s10).7 However, this knowledge has not yet been translated to 
implications for clinical practice. Once dermatologists and other health 
professionals are aware of the large impact of individual and environ-
mental factors that enhance possible placebo and nocebo responses in 
their patients, they could pay more explicit attention to factors such as 
establishing a good doctor–patient relationship, improving the treatment 
adherence of the patient (e.g. by decreasing fear of side effects), or cre-
ating a health- stimulating environment, to optimize treatment effects.
A frequent concern and misunderstanding is that placebo only 
works when patients are not informed about the real mechanisms of 
an inert treatment. Open- label trials have demonstrated, however, 
that even knowing that one receives a placebo leads to beneficial 
treatments effects, such as fewer symptoms for patients with irritable 
bowel syndrome (s37–s39). From an ethical perspective, patients need 
to be informed about the multifactorial influences—including their 
own expectations—that play a role in treatment effects. This might 
at times lead to different treatment choices; for example, a regular 
treatment option might only be started when the patient believes in 
effects of this treatment or a less aggressive treatment strategy might 
be chosen for a patient with an elevated fear of side effects. However, 
the placebo responses and positive expectations of patients will only 
endure if they are based on trust in a long- term authentic relationship. 
Highly optimistic promises followed by limited effects will probably 
result in nocebo instead of placebo effects.
2. Researchers should maximally control for possible placebo effects 
in research designs.
Researchers are interested to know the actual effects of a specific 
new treatment, independently of possible placebo and nocebo effects. 
However, randomized controlled trials usually consist of an intervention 
and a placebo arm, without an additional condition without any treat-
ment. In research designs, a condition without any treatment compo-
nents should be preferably added as a comparison group to get relatively 
precise estimations of the treatment and placebo effects. Moreover, 
eliminating expectancies is the most effective way to control for placebo 
and nocebo effects. For example, in open- hidden paradigms, openly 
administering a treatment can be compared to treatment administra-
tion outside of the patient’s awareness (e.g. hidden machine- regulated 
infusion of drug). An alternative procedure is—after agreement of the 
patient—not to disclose the moment that treatment is administered or 
expected to work. Ideally, trials consist of both blinded and non- blinded 
conditions (open- label designs) that vary in the amount of knowledge 
patients have about the treatment they receive (s4, s40).
3. Dermatologists can be trained to prevent unintended nocebo 
effects.
The large and relevant role of placebo and nocebo effects implies a 
central role of non- pharmacological factors, such as environmental influ-
ences and doctor–patient communication, that substantially contrib-
ute to treatment outcomes. Additional non- pharmacological treatment 
options could be considered for patients particularly at risk for nocebo 
effects, such as patients with numerous side effects due to heightened 
anxiety about possible adverse effects of regular treatments. To prevent 
nocebo effects, it is important to recognize that not all patients benefit 
from being informed in detail about all possible risks and side effects of 
a treatment. In view of ethical standards for informed consent proce-
dures, future guidelines can focus more on the needs of the individual 
patient: information might be tailored to the patient’s coping style, with 
information about risks and side effects available if needed, based on 
evidence- based guidelines on which informed consent procedure is most 
effective for specific subgroups of patients. In addition, general patient 
information material can be developed for all types of treatments to 
inform patients about unintended side effects, for example in the case 
of exaggerated fears about possible risks. In addition, communication 
trainings can support dermatologists in their communication about 
possible placebo and nocebo effects in regular dermatology practice. 
Moreover, specific nocebo- reducing treatments could be developed for 
patients who are, for example, particularly anxious and concerned about 
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possible side effects and risks of a standard treatment. All these factors 
emphasize non- pharmacological treatment components, such as the role 
of open and solid communication and the provision of psychological sup-
port for patients at risk, to decrease possible nocebo effects.
4. Insurance companies, the pharmaceutical industry and research 
foundations should realize that placebo responses can be used 
to optimize treatment outcomes in terms of increased effective-
ness, fewer side effects and lower costs.
In view of the evidence for learned immune functioning based 
on conditioning principles, questions arise as to why these potential 
effects are not more systematically used to optimize our treatments. 
All pharmacological therapies make use of placebo effects, if perhaps 
unintentionally, when a patient starts a new treatment: they promise 
a better outcome. At the same time, the large heterogeneity in the 
long- term efficacy of many treatments might be at least partly a conse-
quence of a lack of enduring placebo effects, as the conditioning effects 
are likely to be extinguished when subjects are not systematically re- 
exposed to the drug on the basis of conditioning principles (s41). The 
results of clinical studies (e.g. for pharmacological treatments in ADHD 
and hormonal ointments in psoriasis) that showed comparable treat-
ment effects or fewer side effects when the dosage of regular treat-
ment was reduced after a period of conditioning9 (s38–s39) support 
the idea that the dosage of medication can be adjusted when making 
full use of possible conditioning effects. This also implies considerable 
possibilities for developing new treatments. Every drug or medication 
can be tested on its ability to enhance its effects by means of condi-
tioning, to produce the same physiological reactions without the drug. 
This knowledge provides important opportunities for new treatment 
developments in terms of higher efficacy, fewer side effects and lower 
treatment costs. This has considerable relevance for research foun-
dations, the pharmacological industry and insurance companies. The 
next challenging step will be to translate this knowledge into regular 
treatment options that make optimal use of a combination of regular 
drug therapy with conditioning principles of our physiological response 
systems, with the ultimate goal of preventing individual treatment fail-
ures and maximizing our treatments for all patients.
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